Daily adaptive radiotherapy to protect salivary glands in head and neck cancer
Compares daily adaptive radiotherapy with standard image-guided radiotherapy in head and neck cancer.
Plain-language title generated from the registry record
Registry title: Phase II Study of Daily Adaptive Radiotherapy for Submandibular Gland-sparing in Head and Neck Cancer
Key facts
- Where
- Toronto, CanadaSee the site
Where in Canada
- Princess Margaret Cancer CentreToronto, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Health Network, Toronto
- Trial code
- NCT07348887
- Record updated
- 4 March 2026
- Original description
This is a randomized, single centre, single blinded prospective study comparing the standard of care imaging guided radiation therapy and daily adaptive radiotherapy (ART) for submandibular gland-sparing in head and neck cancerRead full original descriptionShow less
Phase II Randomized Trial of RT-Led Daily Adaptive Radiotherapy for Submandibular Gland-Sparing in Head and Neck Cancer (RTL-DART)
This is a randomized, single centre, single blinded prospective study comparing the standard of care imaging guided radiation therapy and daily adaptive radiotherapy (ART) for submandibular gland-sparing in head and neck cancer
Inclusion: Age ≥ 18 years; Histologically proven Squamous Cell carcinoma of head and neck; Bilateral neck being treated; At least one level 1b not being treated electively and with no target structure, other than elective level II/III, <1cm to spared SMG; ECOG PS 0-2; Planned for curative (chemo)radiotherapy; Able to receive and understand verbal and written information regarding study and able to give written informed consent; Be able to lie comfortably on back and to wear immobilization for up to 1 hour.
Exclusion: Underlying salivary dysfunction prior to treatment judged by investigator to affect likelihood of benefit from ART; As judged by investigator evidence of systemic disease that makes unsuitable for study; Pregnancy.